Role Of The Addition Of Docetaxel To Adt In Mhspc

Role of the addition of docetaxel to ADT in mHSPC

ARASENS: the addition of darolutamide to ADT and docetaxel for the treatment of mHSPC

ARASENS: dialuramide plus ADT and docetaxel for metastatic hormone-sensitive prostate cancer

Is there still a role for docetaxel in mHSPC?

Addition of docetaxel to initial hormone therapy improves survival in prostate cancer

Is There Still a Role for Docetaxel in mHSPC?

Breakthroughs for Physicians

OS sensitivity analysis of darolutamide, docetaxel and ADT in ARASENS

PEACE-1 points to benefit of adding abiraterone to ADT–docetaxel in de novo mCSPC | Karim Fizazi

Medicine Matters oncology

Dr. Oh on the Role of Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer

Timing of ADT and Chemotherapy

Grand Rounds in Urology

ADT plus docetaxel or bisphosphonates in hormone sensitive prostate cancer: Systemic review

Dr. Kantoff on Evolving Role of Docetaxel in Prostate Cancer Treatment

ARASENS: dialuramide plus ADT and docetaxel in mHSPC stratified by disease risk + volume

Darolutamide, androgen-deprivation therapy and docetaxel demonstrate promising efficacy mHSPC

ARASENS: tolerability + pharmacokinetic analyses of combo therapy with DARO, ADT and DOC in mHSPC

Evaluating triplet therapy in metastatic hormone sensitive prostate cancer

Role of ADT with Radiation

Grand Rounds in Urology

New Approaches to Metastatic Hormone Sensitive Prostate Cancer

Grand Rounds in Urology

CHAARTED: ADT + docetaxel for prostate cancer

New Concepts in ADT

Grand Rounds in Urology